University of California, San Francisco

Joe Conaghan, PhD, HCLD, Named CCRM Fertility's Director of Science and Training

Retrieved on: 
Wednesday, July 5, 2023
University, Education, Pacific Ocean, Embryology, Culture, Teaching, University of California, San Francisco, San Francisco State University, Royal Postgraduate Medical School, Research, Doctor of Philosophy, IVF, Science, Andrology, Fertility, Metabolism, Patient, UCSF, SAN, Hammersmith Hospital, Science and technology in Asia, Emil Steinberger (endocrinologist), Nursing, Birth control

SAN FRANCISCO, July 5, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, has named Joe Conaghan, PhD, HCLD, as the director of science and education. An internationally recognized embryologist, Dr. Conaghan is a board-certified high-complexity clinical laboratory director in the disciplines of embryology and andrology. In his new role at CCRM Fertility, he will be responsible for overseeing the network's West Coast lab operations; leading informative internal lab training initiatives to support embryologists' continuing education; and helping manage network research and presentations internally and for industry initiatives.

Key Points: 
  • SAN FRANCISCO, July 5, 2023 /PRNewswire/ -- CCRM Fertility , the global pioneer in fertility treatment, research and science, has named Joe Conaghan, PhD, HCLD, as the director of science and education.
  • An internationally recognized embryologist, Dr. Conaghan is a board-certified high-complexity clinical laboratory director in the disciplines of embryology and andrology.
  • "It's an honor to have a hand in elevating CCRM Fertility's cutting-edge lab operations," said Dr. Conaghan.
  • To learn more about CCRM Fertility, please visit ccrmivf.com/ .

ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer

Retrieved on: 
Thursday, June 29, 2023
Technology, Men, Health, Biometrics, Consumer, Artificial Intelligence, Oncology, Other Science, Other Technology, Research, Medical Devices, General Health, Science, Clinical Trials, University, The New England Journal of Medicine, University of California, San Francisco, University Hospitals Cleveland Medical Center, Radiation, ADT, Prostate, CWRU, Radiation therapy, NEJM, MD, Patient, Disease, AI, Urology, Medicine, Prostate cancer, Medical imaging

ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

Key Points: 
  • ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.
  • In past U.S.-based clinical trials, African American men have made up only 10.8% of prostate cancer trial participants .
  • If given the opportunity to leverage the biomarker, most intermediate-risk patients could potentially avoid the morbidity and financial burden associated with ADT.
  • We celebrate this achievement while also looking ahead to how we can build upon this evidence to continue transforming care for men diagnosed with localized prostate cancer.”
    For more information on ArteraAI, visit Artera.ai .

Rapport Therapeutics Names Scientific Advisory Board

Retrieved on: 
Thursday, June 29, 2023
Health, Neurology, Other Science, Clinical Trials, Research, Science, Biotechnology, Molecular biology, Baylor University, Temperature, Howard Hughes Medical Institute, Genetics, Journal, National Academy of Medicine, Patient, Nervous system, Catalysis, RAPS, Eurosport 1, Royal Society, SAB, Nobel Prize, National academy, University, Emeritus, American Epilepsy Society, Janelia Research Campus, Royal, Princess of Asturias Awards, System, Scientific method, Safety, HHMI, Third Rock Ventures, FRS, Shaw Prize, Therapy, Epilepsy, Central nervous system, McMillan, RAP, NAS, Baylor College of Medicine, Nobel Prize in Chemistry, University of California, San Francisco, DSM-IV codes, American Academy, Buckingham Palace, Princeton University, Harvard Medical School, Nobel, United Kingdom, Nerve injury, Gene, Pharmaceutical industry, Chemistry, Rapport, Neuroscience, Pain, Physiology, Nature, Anatomy, Medicine

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.
  • Its members are David Julius, Ph.D., David MacMillan, Ph.D., David Clapham, M.D., Ph.D., Allan Basbaum, Ph.D., FRS and Jeffrey Noebels, M.D., Ph.D.
  • “Rapport has assembled what may well be the most impressive scientific advisory board in biotech, which includes some of the world’s most accomplished scientists,” said Steve Paul, M.D., Chairman of the Rapport Board of Directors, Co-Founder and Advisory Partner at Third Rock Ventures.
  • Dr. Clapham was HHMI’s vice president and chief scientific officer from 2016 to 2022.

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Retrieved on: 
Wednesday, June 28, 2023
FNIH, University, Neoplasm, University of California, San Francisco, Clinical trial, Breast, Woman, EOP, Bangladesh Technical Education Board, Biomarker, SERM, Quantum Leap, Patient, Risk, SAN, FDA, Therapy, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Breast cancer, Pharmaceutical industry

The I-SPY 2 TRIAL is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium.

Key Points: 
  • The I-SPY 2 TRIAL is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium.
  • The (Z)-endoxifen treatment arm, which is expected to enroll approximately 20 patients, is part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP).
  • Patients will receive 10 mg of (Z)-endoxifen daily for up to 24 weeks prior to surgery.
  • But one of the biggest challenges in breast cancer is the hormone positive breast cancers that are slow growing.

Tuned Launches Innovative Pediatric Hearing Care Program

Retrieved on: 
Tuesday, June 27, 2023
Learning, Insurance, Communication, University, Pediatrics, Language development, IPad, Noise, Hearing loss, Speech, Parent, University of California, San Francisco, ADHD, Brain, Tuning fork, Language, School, Noise-induced hearing loss, Patient, Risk, Hearing, Reading, Entrepreneurship, Ageing, Research, Behavior, Dentistry, Nursing

Offered as an employer-sponsored benefit, Tuned's innovative pediatric program combines modern hearing knowledge and technology with teleaudiology to modernize a testing method that has not changed for almost 50 years.

Key Points: 
  • Offered as an employer-sponsored benefit, Tuned's innovative pediatric program combines modern hearing knowledge and technology with teleaudiology to modernize a testing method that has not changed for almost 50 years.
  • Children with hearing loss are often overlooked, leaving them to languish in schools, undiagnosed and untreated, at risk for developmental delays .
  • "Hearing loss has always been ignored because it can't be seen, and most people don't understand the connection between hearing and learning.
  • The program includes care navigation, which helps parents navigate potential treatments or solutions, which include understanding what local assistance is available.

Developing Next-Gen Scientific Leaders: The Parker Institute for Cancer Immunotherapy Awards up to $2.9 Million to Eight Early Career Investigators

Retrieved on: 
Tuesday, June 27, 2023
Research, Hospitals, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, San Francisco, Computational biology, University, Freedom, Systems biology, Neoplasm, University of California, San Francisco, Cancer, Multimedia, Mount Sinai, Cell, Immunotherapy, Doctor of Philosophy, Icahn School of Medicine at Mount Sinai, B cell, CAR, MD, Patient, Immune system, Stanford University School of Medicine, Escape Room, Faculty, Gladstone Institutes, Tumor microenvironment, Parker Bridge, Metastasis, Prostate cancer, Pharmaceutical industry, Nursing, Vaccine, Management, Medical imaging, Stanford University, Medicine

​Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy (PICI) continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

Key Points: 
  • ​Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy (PICI) continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.
  • “Not only do we invest in today’s preeminent scientists, we also empower the cancer immunotherapy leaders of tomorrow,” said John Connolly, PhD, Chief Scientific Officer at PICI.
  • Rounding out this year’s class are five Parker Scholars, scientists who are ready to establish a laboratory or independent program in cancer immunotherapy.
  • Early career researchers also have access to leading-edge technology and other top collaborators to further guide and propel research.

SandboxAQ Announces Bio-Pharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions

Retrieved on: 
Saturday, June 24, 2023
DMRG, San Francisco, TPU, Partnership, Post, PALO, Columbia University Irving Medical Center, Ligand, Pulitzer Prize, University of California, San Francisco, Cancer, Research, AstraZeneca, Drug design, AQ, DFT, Alzheimer's disease, Pulitzer, Parkinson's disease, UC, MD, UCSF, Patient, Drug discovery, Sanofi, Neurodegenerative disease, AI, Fine chemical, Pharmaceutical industry, Medical device

PALO ALTO, Calif., June 23, 2023 /PRNewswire-PRWeb/ --  After several years of stealth development, SandboxAQ today formally announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers and partners. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer's, Parkinson's, and other conditions. The company is collaborating with a range of bio-pharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco.

Key Points: 
  • The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer's, Parkinson's, and other conditions.
  • Paul Hudson, CEO of Sanofi said, "We are very interested in the work SandboxAQ is doing to revolutionize drug discovery and development via in-silico simulation of molecular interactions using AI and quantum technologies.
  • "SandboxAQ is at the forefront of combining AI and quantum techniques to address large, enterprise challenges.
  • SandboxAQ's technology is revolutionizing the drug discovery and development process," said Eric Schmidt, Chairman of the Board of SandboxAQ."

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

Retrieved on: 
Tuesday, June 20, 2023
Software, Research, General Health, Consumer, Technology, Infectious Diseases, University, Education, Science, Biotechnology, Other Science, Health, Metagenomics, Institute of Biochemistry and Biophysics, Bio, GV, Infection, University of California, San Francisco, Section 32, Encephalitis, DRS, Innovation, Genomics, Cerebrospinal fluid, Fungus, Technology management, Biochemistry, Dicarboxylic acid, Chan Zuckerberg Biohub, Patient, UCSF, Parasitism, Biophysics, OTMA, Diagnosis, Bacteria, Foundation Medicine, Virus, Meningitis, Pharmaceutical industry, Vaccine

The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests.

Key Points: 
  • The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests.
  • Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti and Matthew Meyerson – world leaders in genomics, metagenomics, and infectious disease.
  • “While genomic testing has been transformative for oncology, rare disease and women’s health, infectious disease has been largely overlooked,” said Brad Murray, co-founder and CEO of Delve.
  • “We firmly believe that mNGS delivers the most conclusive, unbiased and actionable diagnosis of infectious disease,” said Joe DeRisi, Ph.D., Delve Bio co-founder, professor of Biochemistry and Biophysics at UCSF, and president of the Chan Zuckerberg Biohub.

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Retrieved on: 
Monday, June 12, 2023
US Foods, Drug development, University, University of California, San Francisco, ADHD, USD, Doctor of Philosophy, Trial of the century, C, Plant, Patient, UCSF, Medical Center, Ophthalmology, Psychiatry, Phase, Grandview, Pharmaceutical industry, Neuroscience

The UCSF site, led by Professor Keith McBurnett, PhD, Psychiatry UCSF Weill Institute for Neurosciences, joins the five (5) Taiwan sites that have begun patient enrollment for the Company’s ADHD Phase II Part 2 clinical study.

Key Points: 
  • The UCSF site, led by Professor Keith McBurnett, PhD, Psychiatry UCSF Weill Institute for Neurosciences, joins the five (5) Taiwan sites that have begun patient enrollment for the Company’s ADHD Phase II Part 2 clinical study.
  • The study entitled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II” is a randomized, double-blind, placebo-controlled study involving a total of approximately one hundred (100) patients in the United States and Taiwan.
  • A total of fifty-three (53) participants have been enrolled and forty-three (43) have completed the eight-week study thus far.
  • “We are pleased to see the first subject enrolled and a few more subjects currently being screened for the ADHD Phase II Part 2 study at UCSF,” said Dr. Howard Doong, ABVC BioPharma’s Chief Executive Officer.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .